These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30852532)

  • 21. Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review.
    Szabo SM; Audhya IF; Malone DC; Feeny D; Gooch KL
    Qual Life Res; 2020 Mar; 29(3):593-605. PubMed ID: 31811595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of quality of life themes in Duchenne muscular dystrophy for patients and carers.
    Uttley L; Carlton J; Woods HB; Brazier J
    Health Qual Life Outcomes; 2018 Dec; 16(1):237. PubMed ID: 30567556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy.
    Staunton H; Trennery C; Arbuckle R; Guridi M; Zhuravleva E; Furlong P; Fischer R; Hall R
    Health Qual Life Outcomes; 2021 Jul; 19(1):184. PubMed ID: 34311756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adapting traditional content validation methods to fit purpose: an example with a novel video assessment and training materials in Duchenne muscular dystrophy (DMD).
    White MK; Leffler M; Rychlec K; Jones C; McSherry C; Walker L; Kosinski M
    Qual Life Res; 2019 Nov; 28(11):2979-2988. PubMed ID: 31302840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Producing a preference-based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes: A mixed-methods research protocol.
    Carlton J; Powell P; Rowen D; Broadley M; Pouwer F; Speight J; Heller S; Gall MA; Rosilio M; Child CJ; Comins J; McCrimmon RJ; de Galan B; Brazier J;
    Diabet Med; 2023 Mar; 40(3):e15007. PubMed ID: 36398992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study.
    Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmüller H; Bushby K
    Dev Med Child Neurol; 2016 May; 58(5):508-15. PubMed ID: 26483095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of the self-efficacy scale in caregivers of Duchenne muscular dystrophy patients.
    Türken A; Çapar H; Çakmak C; Kurt ME; Menteş N
    Work; 2024; 78(2):431-440. PubMed ID: 38143409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy.
    Landfeldt E; Iff J; Henricson E;
    Value Health; 2021 Oct; 24(10):1490-1498. PubMed ID: 34593173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using an Online, Modified Delphi Approach to Engage Patients and Caregivers in Determining the Patient-Centeredness of Duchenne Muscular Dystrophy Care Considerations.
    Khodyakov D; Grant S; Denger B; Kinnett K; Martin A; Booth M; Armstrong C; Dao E; Chen C; Coulter I; Peay H; Hazlewood G; Street N
    Med Decis Making; 2019 Nov; 39(8):1019-1031. PubMed ID: 31722623
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.
    Landfeldt E; Alfredsson L; Straub V; Lochmüller H; Bushby K; Lindgren P
    Pharmacoeconomics; 2017 Feb; 35(2):249-258. PubMed ID: 27798808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy and comorbid attention-deficit hyperactivity disorder using propensity-score matching.
    Xu RH; Dai Y; Ng SSM; Zhang S; Dong D
    J Affect Disord; 2023 Jul; 333():147-153. PubMed ID: 37084967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Self-reported quality of life and depressive symptoms in children, adolescents, and adults with Duchenne muscular dystrophy: a cross-sectional survey study.
    Elsenbruch S; Schmid J; Lutz S; Geers B; Schara U
    Neuropediatrics; 2013 Oct; 44(5):257-64. PubMed ID: 23794445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health.
    Bendixen RM; Senesac C; Lott DJ; Vandenborne K
    Health Qual Life Outcomes; 2012 May; 10():43. PubMed ID: 22545870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reliability and validity of the Chinese version of the Pediatric Quality Of Life InventoryTM (PedsQLTM) 3.0 neuromuscular module in children with Duchenne muscular dystrophy.
    Hu J; Jiang L; Hong S; Cheng L; Kong M; Ye Y
    Health Qual Life Outcomes; 2013 Mar; 11():47. PubMed ID: 23497421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study.
    Crossnohere NL; Fischer R; Lloyd A; Prosser LA; Bridges JFP
    Med Decis Making; 2021 Feb; 41(2):209-221. PubMed ID: 33463405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life and informal care burden associated with duchenne muscular dystrophy in Portugal: the COIDUCH study.
    Andreozzi V; Labisa P; Mota M; Monteiro S; Alves R; Almeida J; Vandewalle B; Felix J; Buesch K; Canhão H; Beitia Ortiz de Zarate I
    Health Qual Life Outcomes; 2022 Mar; 20(1):36. PubMed ID: 35241084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Confirmatory validation of the french version of the Duchenne Muscular Dystrophy module of the pediatric quality of life inventory (PedsQL
    Wallach E; Ehlinger V; Biotteau M; Walther-Louvier U; Péréon Y; Vuillerot C; Fontaine S; Sabouraud P; Espil-Taris C; Cuisset JM; Laugel V; Baudou E; Arnaud C; Cances C
    BMC Pediatr; 2023 Nov; 23(1):563. PubMed ID: 37968589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation.
    Hind D; Parkin J; Whitworth V; Rex S; Young T; Hampson L; Sheehan J; Maguire C; Cantrill H; Scott E; Epps H; Main M; Geary M; McMurchie H; Pallant L; Woods D; Freeman J; Lee E; Eagle M; Willis T; Muntoni F; Baxter P
    Health Technol Assess; 2017 May; 21(27):1-120. PubMed ID: 28627356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing validity of the EQ-5D-5L proxy in children and adolescents with Duchenne muscular dystrophy or spinal muscular atrophy.
    Xu RH; Dai Y; Ng SSM; Tsang HWH; Zhang S; Dong D
    Eur J Health Econ; 2024 Feb; 25(1):103-115. PubMed ID: 36809586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysis.
    Landfeldt E; Mayhew A; Straub V; Lochmüller H; Bushby K; Lindgren P
    Muscle Nerve; 2018 Sep; 58(3):367-373. PubMed ID: 29466827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.